181 related articles for article (PubMed ID: 17133160)
21. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
22. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
[TBL] [Abstract][Full Text] [Related]
23. Abacavir (Ziagen(®)) use between 2003 and 2008 in France according to the electronic medical record NADIS(®).
Dellamonica P; Katlama C; Lévy-Bachelot L; Daures JP; Finkielsztejn L
Med Mal Infect; 2013 Dec; 43(11-12):467-74. PubMed ID: 24262915
[TBL] [Abstract][Full Text] [Related]
24. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
[TBL] [Abstract][Full Text] [Related]
25. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
[TBL] [Abstract][Full Text] [Related]
26. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
27. New abacavir data open door to a better treatment paradigm.
AIDS Alert; 1998 Aug; 13(8):85-7. PubMed ID: 11365647
[TBL] [Abstract][Full Text] [Related]
28. Abacavir and lamivudine for the treatment of human immunodeficiency virus.
Rizzardini G; Zucchi P
Expert Opin Pharmacother; 2011 Sep; 12(13):2129-38. PubMed ID: 21787242
[TBL] [Abstract][Full Text] [Related]
29. Sweet's syndrome following abacavir therapy.
Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
[No Abstract] [Full Text] [Related]
30. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.
Lanier ER; Ait-Khaled M; Scott J; Stone C; Melby T; Sturge G; St Clair M; Steel H; Hetherington S; Pearce G; Spreen W; Lafon S
Antivir Ther; 2004 Feb; 9(1):37-45. PubMed ID: 15040535
[TBL] [Abstract][Full Text] [Related]
31. Preliminary report on 1592.
AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756
[TBL] [Abstract][Full Text] [Related]
32. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.
Staprans S; Marlowe N; Glidden D; Novakovic-Agopian T; Grant RM; Heyes M; Aweeka F; Deeks S; Price RW
AIDS; 1999 Jun; 13(9):1051-61. PubMed ID: 10397535
[TBL] [Abstract][Full Text] [Related]
33. Anti-HIV agents. Abacavir once or twice daily.
TreatmentUpdate; 2005; 17(5):8. PubMed ID: 17219659
[No Abstract] [Full Text] [Related]
34. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
Bogoch II; Davis BT; Venna N
J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
[TBL] [Abstract][Full Text] [Related]
35. Once-daily abacavir in place of twice-daily administration.
Goedken AM; Herman RA
Ann Pharmacother; 2005; 39(7-8):1302-8. PubMed ID: 15956231
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children.
Palumbo PE; Raskino C; Fiscus S; Pahwa S; Fowler MG; Spector SA; Englund JA; Baker CJ
JAMA; 1998 Mar; 279(10):756-61. PubMed ID: 9508151
[TBL] [Abstract][Full Text] [Related]
37. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
James JS
AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
[TBL] [Abstract][Full Text] [Related]
38. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
Bellagamba R; Tommasi C; De Marco M; Narciso P
J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
[No Abstract] [Full Text] [Related]
39. Abacavir pharmacogenetics--from initial reports to standard of care.
Martin MA; Kroetz DL
Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
[TBL] [Abstract][Full Text] [Related]
40. Next HIV guidelines likely to include salvage therapy.
AIDS Alert; 1999 Jul; 14(7):76-8. PubMed ID: 11366417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
